Home›Stock Screener›Indoco Remedies

Indoco Remedies Share Price Today | Stock Price & Indoco Remedies Share Screener

INDOCO Pharmaceuticals & Biotechnology
Live Share Price NSE
₹233.08
▼ -8.93 (-3.69%)
2026-11-19 00:00:00
Live Share Price BSE
₹233.35
▼ -7.80 (-3.23%)
2026-11-19 00:00:00

As of November 19, 2026, the live Indoco Remedies share price (NSE: INDOCO) is ₹233.08 on NSE and ₹233.35 on BSE, down 3.69% from the previous close, with shares trading between ₹231.11 and ₹239.73 in today's trading session, and a 52-week range of ₹164.00–₹273.77. Track Indoco Remedies market cap to gauge the company's total market size. Use the Indoco Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Indoco Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹546 and net income of ₹20, with EBITDA of ₹72, an operating margin of 7.0% and a profit margin of 3.7%.

Indoco Remedies Market Cap ₹2,096.58 Cr.
INDOCO P/E Ratio (TTM) 66.40
Indoco Remedies P/B Ratio 2.06
EPS (TTM) ₹-10.70
Dividend Yield 0.09%
Debt to Equity 1.06
INDOCO 52 Week High ₹273.77
Indoco Remedies 52 Week Low ₹164.00
Operating Margin 7.00%
Profit Margin 3.66%
INDOCO Revenue (TTM) ₹546.00
EBITDA ₹72.00
Net Income ₹20.00
Total Assets ₹2,593.00
Total Equity ₹932.00

Indoco Remedies Share Price Chart

Track the current stock price of Indoco Remedies with an interactive chart. Analyse INDOCO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Indoco Remedies stock quote in one place.

The quote of ₹233.08 sits between the 52-week low of ₹164.00 and the 52-week high of ₹273.77, and the latest session moved -3.69% from the previous close.

Indoco Remedies Company Profile - Fundamental Screener

Screen Indoco Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for INDOCO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE873D01024.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE873D01024

Indoco Remedies Balance Sheet Screener

Screen INDOCO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,593, up from ₹2,430 in 2025.

Latest statistics put total assets at ₹2,593 and shareholder funds at ₹932, with a leverage ratio of 1.06.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 2,593 2,430 2,145 1,658 1,486 1,315 1,272 1,258 1,236 1,197
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1,193 997 954 678 555 570 590 468 489 440

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 609 604 422 205 157 139 133 152 146 155
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 932 1,018 1,111 1,028 905 769 680 661 675 651
Share Capital 19 18 18 18 18 18 18 18 18 18
Reserves & Surplus 921 1,004 1,092 1,010 886 751 661 642 657 633

Indoco Remedies Income Statement Screener - Profit & Revenue Analysis

Screen Indoco Remedies income statement and profit fundamentals. Analyze INDOCO quarterly results. Indoco Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹546 and net profit was ₹20, equal to earnings per unit of ₹2.11, at an operating margin of 7%.

In that period expenses were ₹474, interest cost ₹27 and tax ₹5. The next period listed, 2026-Jun, shows revenue of ₹566 and net profit of ₹65.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 546 566 460 435 473 433 386 404 432 425 462 461 478 417 429
Expenses 474 427 426 420 442 422 391 399 392 384 401 405 410 365 363

Operating Costs and Margins

EBITDA 72 139 34 15 30 10 -5 6 40 42 61 56 68 52 66
Operating Profit % 7.00% 9.00% 7.00% 3.00% 6.00% 2.00% -2.00% 1.00% 9.00% 10.00% 9.00% 12.00% 13.00% 12.00% 15.00%
Depreciation 34 35 33 32 32 30 29 29 29 28 26 24 21 20 18
Interest 27 28 46 26 25 26 18 16 18 14 12 10 8 8 9

Profit and Earnings

Profit Before Tax 24 78 -25 -31 -14 -37 -46 -31 -5 7 33 23 46 34 39
Tax 5 12 -1 -2 -4 0 -4 -3 5 5 11 7 11 10 13
Net Profit 20 65 -24 -30 -9 -36 -41 -28 -10 2 22 16 35 24 26
EPS 2.11 7.09 -2.57 -3.20 -1.00 -3.94 -4.48 -3.08 -1.09 0.20 2.39 1.69 3.82 2.62 2.80

Indoco Remedies Cash Flow Screener - Liquidity Fundamentals

Screen INDOCO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹192, and net cash flow was an inflow of ₹14.

Over the same period, investing activities used ₹102 and financing activities used ₹77.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 192 95 157 179 174 82 123 132 123 89
Investing Activities -102 -339 -433 -208 -121 -67 -56 -104 -135 -171

Financing and Net Cash

Financing Activities -77 241 280 23 -44 -30 -64 -16 -39 132
Net Cash Flow 14 -3 4 -7 8 -14 3 12 -52 50

Indoco Remedies Shareholding Pattern Screener

See Indoco Remedies shareholding pattern with promoter, FII, and DII holdings. Check Indoco Remedies promoter holding and ownership changes for INDOCO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 58.86%, foreign institutions 0.94%, domestic institutions 18.15% and the public 16.56%, spread across 32,276 shareholders.

The shareholder count was 32,276 in 2026-Mar, compared with 32,457 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 58.86% 58.86% 58.92% 58.90% 58.90% 58.90% 58.90% 58.72%

Institutional Investors

FII Holding 0.94% 1.27% 1.64% 1.24% 1.22% 1.25% 1.10% 1.91%
DII Holding 18.15% 17.68% 16.64% 18.75% 18.96% 18.16% 18.15% 19.41%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.56% 16.68% 16.94% 15.99% 15.79% 16.40% 16.48% 15.33%
Other Holding 5.48% 5.50% 5.86% 5.12% 5.14% 5.29% 5.38% 4.62%
Shareholder Count 32,276 32,457 34,098 34,497 33,129 33,319 32,659 33,201

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Indoco Remedies. Indoco Remedies dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.20 per unit for 2026-March, a yield of 0.09%, compared with ₹0.20 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.20, ₹0.20 and ₹1.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.20 0.09%
2025-March ₹0.20 0.12%
2024-March ₹1.50 0.64%
2023-March ₹2.25 0.68%
2022-March ₹2.25 0.69%
2021-March ₹1.50 0.40%
2020-March ₹0.30 0.10%
2019-March ₹0.30 0.14%
2018-March ₹1.00 0.49%
2017-March ₹1.60 0.75%

Indoco Remedies Stock Index Membership - Nifty & Sensex

See which indices include Indoco Remedies stock. Check INDOCO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Indoco Remedies Market Events Screener - Corporate Actions

Get Indoco Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Indoco Remedies stock events that may affect INDOCO share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.

It is followed by Annual General Meeting dated September 17, 2026 and Dividend dated September 10, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-27 2026-10-27 Quarterly Result Announcement NA -3.04%
2026-09-17 2026-09-17 Annual General Meeting NA 14.56%
2026-09-10 2026-09-10 Dividend ₹ 0.20 /share 1.43%
2026-07-28 2026-07-28 Quarterly Result Announcement NA -0.31%
2026-05-07 2026-05-07 Quarterly Result Announcement NA 10.47%
2026-02-03 2026-02-03 Quarterly Result Announcement NA 0.46%
2025-11-06 2025-11-06 Quarterly Result Announcement NA -7.97%
2025-09-11 2025-09-11 Annual General Meeting NA -5.74%
2025-09-04 2025-09-04 Dividend ₹ 0.20 /share 8.04%
2025-07-24 2025-07-24 Quarterly Result Announcement NA -4.86%
2025-05-22 2025-05-22 Quarterly Result Announcement NA 4.17%
2025-01-21 2025-01-21 Quarterly Result Announcement NA 2.60%
2024-10-24 2024-10-24 Quarterly Result Announcement NA -4.96%
2024-09-26 2024-09-26 Annual General Meeting NA 0.00%
2024-09-19 2024-09-19 Dividend ₹ 1.50 /share 12.85%

Indoco Remedies Competitors Screener - Peer Stocks Comparison

Screen INDOCO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Indoco Remedies Company Announcements - News & Reports Screener

Screen INDOCO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 13, 2026 and November 11, 2026.

Date Update Actions
2026-11-17 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-13 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-11 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-10 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-04 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-03 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-29 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-10-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-27 Approval Of The Financial Results For The Quarter And Half Year Ended 30Th September 2026 -
2026-10-27 Board Meeting Outcome for Outcome Of Board Meeting Held On 27Th October 2026 -
2026-10-27 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-10-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-14 Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-29 Intimation To Shareholders Holding Shares In Physical Mode Regarding Mandatory Furnishing Of PAN KYC And Bank Details As Per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 Dated February 6 2026 -
2026-09-28 Announcement under Regulation 30 (LODR)-Acquisition -
2026-09-28 Closure of Trading Window -
2026-09-24 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹233.08, within a 52-week range of ₹164.00 to ₹273.77. The P/E ratio is 66.40 and the P/B ratio is 2.06, with earnings per unit of ₹-10.70. Market capitalisation stands at ₹2,096.58 Cr and the dividend yield is 0.09%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.